Literature DB >> 23676834

Nondialyzable uremic toxins.

Marta Piroddi1, Desireé Bartolini, Silvia Ciffolilli, Francesco Galli.   

Abstract

Nondialyzable uremic toxins can be defined as solutes producing adverse biological effects that consequently to peculiar physicochemical features (mainly their large size and hydrophobic character) cannot leave the blood stream through a dialysis membrane. These are the subject of great interest for the scientific community, in that emerging evidence suggests that such uremic retention solutes may contribute a main role to the complex inflammatory and vascular comorbidity of the uremic syndrome. Treatments based on most efficient diffusive or convective protocols of dialysis and pharmacological therapies cannot prevent nor correct such clinical symptoms. Protein-bound solutes and other proteinaceous components present in excess in the uremic milieu are thus natural candidates for explaining the resistance of uremic toxicity to current regimens of therapy. Intense research is in progress to identify molecular species and mechanisms of toxicity, but the real challenge of our times is to develop innovative clinical protocols that may remove or prevent the formation/toxicity of nondialyzable uremic solutes. These include high-efficacy protein-leaking dialyzers, adsorption techniques, frequent dialysis, and pharmacological therapies. These aspects are examined in this review paper, paying particular attention to covalent posttranslational modifications of plasma proteins produced as a consequence of oxidative, nitrosative and carbonyl stress. These represent an emerging trait in the pathobiology of inflammatory and age-related disorders, deserving further consideration in chronic kidney disease.
Copyright © 2013 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23676834     DOI: 10.1159/000350846

Source DB:  PubMed          Journal:  Blood Purif        ISSN: 0253-5068            Impact factor:   2.614


  7 in total

1.  Uremic metabolites impair skeletal muscle mitochondrial energetics through disruption of the electron transport system and matrix dehydrogenase activity.

Authors:  Trace Thome; Zachary R Salyers; Ravi A Kumar; Dongwoo Hahn; Fabian N Berru; Leonardo F Ferreira; Salvatore T Scali; Terence E Ryan
Journal:  Am J Physiol Cell Physiol       Date:  2019-07-10       Impact factor: 4.249

Review 2.  Reconsidering adsorption in hemodialysis: is it just an epiphenomenon? A narrative review.

Authors:  Nans Florens; Fitsum Guebre-Egziabher; L Juillard
Journal:  J Nephrol       Date:  2021-04-10       Impact factor: 3.902

3.  Indoxyl sulfate impairs angiogenesis via chronic aryl hydrocarbon receptor activation.

Authors:  Zachary R Salyers; Madeline Coleman; Nicholas P Balestrieri; Terence E Ryan
Journal:  Am J Physiol Cell Physiol       Date:  2021-01-06       Impact factor: 4.249

Review 4.  Modified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic Toxins.

Authors:  Nans Florens; Catherine Calzada; Egor Lyasko; Laurent Juillard; Christophe O Soulage
Journal:  Toxins (Basel)       Date:  2016-12-16       Impact factor: 4.546

5.  Tissue-Specific 1H-NMR Metabolomic Profiling in Mice with Adenine-Induced Chronic Kidney Disease.

Authors:  Ram B Khattri; Trace Thome; Terence E Ryan
Journal:  Metabolites       Date:  2021-01-10

6.  Basic inflammatory indices and chosen neutrophil receptors expression in chronic haemodialysed patients.

Authors:  Zbigniew Baj; Zbigniew Zbróg; Adam Szuflet; Sylwia Mańka; Piotr Bartnicki; Ewa Majewska
Journal:  Cent Eur J Immunol       Date:  2018-06-30       Impact factor: 2.085

7.  Chronic kidney disease exacerbates ischemic limb myopathy in mice via altered mitochondrial energetics.

Authors:  Fabian N Berru; Sarah E Gray; Trace Thome; Ravi A Kumar; Zachary R Salyers; Madeline Coleman; Kerri O'Malley; Leonardo F Ferreira; Scott A Berceli; Salvatore T Scali; Terence E Ryan
Journal:  Sci Rep       Date:  2019-10-29       Impact factor: 4.379

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.